Native name | Εθνική Εκστρατεία Εμβολιασμού «Επιχείρηση Ελευθερία» |
---|---|
Date | 27 December 2020 – present |
Location | Greece |
Cause | COVID-19 pandemic in Greece |
Target | Full immunisation of people in Greece against COVID-19 |
Participants | 21.091.153 doses administered (30 June 2022) 7.919.254 have received at least one vaccine dose (30 June 2022) 75.4% 72.6% 58.2% |
Website | Official Website |
The COVID-19 vaccination campaign in Greece began on 27 December 2020. [1] As of the 30th of June 2022, 7.919.254 people have received their first dose (75.4% of total population), and 7.629.060 people have been fully vaccinated (72.6% of total population). A total of 6.119.231 people have received an additional booster shot (58.2% of total population). [2]
There are several COVID-19 vaccines at various stages of development around the world.
Vaccine | Approval | Deployment |
---|---|---|
Pfizer–BioNTech | 21 December 2020 | 27 December 2020 |
Moderna | 6 January 2021 | 12 January 2021 |
Oxford-AstraZeneca | 29 January 2021 | 7 February 2021 |
Janssen | 11 March 2021 | 5 May 2021 |
Novavax | 20 December 2021 | 5 March 2022 |
The COVID-19 pandemic in Latvia was a part of the worldwide pandemic of coronavirus disease 2019 caused by severe acute respiratory syndrome coronavirus 2. The virus was confirmed to have reached Latvia on 2 March 2020, having been brought along with people returning from abroad.
The COVID-19 pandemic was confirmed to have reached the French overseas collectivity of New Caledonia on 18 March 2020. All cases are on the main island of Grand Terre and are related to travel abroad. On 7 May, all cases had recovered.
The Sinopharm BIBP COVID-19 vaccine, also known as BBIBP-CorV, the Sinopharm COVID-19 vaccine, or BIBP vaccine, is one of two whole inactivated virus COVID-19 vaccines developed by Sinopharm's Beijing Institute of Biological Products. It completed Phase III trials in Argentina, Bahrain, Egypt, Morocco, Pakistan, Peru, and the United Arab Emirates (UAE) with over 60,000 participants. BBIBP-CorV shares similar technology with CoronaVac and Covaxin, other inactivated virus vaccines for COVID-19. Its product name is SARS-CoV-2 Vaccine, not to be confused with the similar product name of CoronaVac.
The COVID-19 vaccination programme in the United Kingdom is an ongoing mass immunisation campaign for coronavirus disease 2019 (COVID-19) during the COVID-19 pandemic in the United Kingdom.
Vaccination against COVID-19 in Sweden started on 27 December 2020 after the approval of the Pfizer–BioNTech vaccine by the European Commission. In Sweden, the Public Health Agency has been commissioned by the government to create a vaccination plan. Sveriges riksbank, the central bank of Sweden, predicts that efficient vaccination against COVID-19 has macroeconomic benefits. As of 20 April 2022, 87.1% of people in Sweden have received at least one dose, with a total of 21,491,717 doses administered. At least one vaccine has been approved for all age groups 12 and older. Children younger than 12 in high risk groups can also be vaccinated.
India began administration of COVID-19 vaccines on 16 January 2021. As of 4 March 2023, India has administered over 2.2 billion doses overall, including first, second and precautionary (booster) doses of the currently approved vaccines. In India, 95% of the eligible population (12+) has received at least one shot, and 88% of the eligible population (12+) is fully vaccinated.
The COVID-19 vaccination campaign in Albania is a mass immunization campaign that was put in place by the Albanian authorities in order to respond to the ongoing COVID-19 pandemic. It started on 11 January 2021.
The COVID-19 vaccination campaign in Russia is an ongoing mass immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country. Russia became the first country to begin a mass COVID-19 vaccination programme on 5 December 2020, starting with primarily doctors, medical workers and teachers. In January 2021, this was extended to the entire population.
On 22 February 2021, Zimbabwe launched their national COVID-19 vaccination program using the Sinopharm BIBP vaccine. As of 17 June 2022, 6,260,228 people have received their first dose, 4,598,703 have received their second dose, and 851,874 have received a third dose.
On 29 January 2021, Algeria launched a COVID-19 vaccination campaign, a day after receiving its first shipment of 50,000 doses of the Russia's Sputnik V vaccine. As of 6 June 2021, around 2.5 million doses have been administered. Algeria is currently vaccinating its population with both Sputnik V and Oxford-AstraZeneca vaccines.
COVID-19 vaccination in Angola is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country. As of 15 June 2021, Angola has administered 1,314,375 doses of vaccines.822,109 people with the first dose and 492,266 people fully vaccinated. Angola began their vaccination program shortly after receiving their first shipment of Oxford AstraZeneca vaccine in early March 2021.
COVID-19 vaccination programs have begun in many countries and territories in Africa. In June 2021, the World Health Organization predicted that 47 of Africa's 54 nations would fall short of the aim of vaccinating 10% of their people by September 2021. In June, Africa accounted for fewer than 1% of worldwide vaccine doses delivered. Africa received in total less than 2% of the 3 billion vaccination doses provided globally.
During the COVID-19 pandemic in Croatia, vaccination against COVID-19 began on 27 December 2020. The Croatian government ordered vaccines together with the EU. 8.7 million doses have been ordered. As of 3 February 2022, over 2.2 million people were fully vaccinated, corresponding to a 63% vaccination rate of the country's population.
COVID-19 vaccination in Nigeria is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country. Vaccination began on 5 March 2021. As of 28 February 2022, 17,914,944 people have received their first dose a COVID-19 vaccine, and 8,197,832 have received their second dose.
The COVID-19 vaccination campaign in Germany began on 26 December 2020.
The COVID-19 vaccination in Singapore is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country. Singapore has a very high vaccination rate, with more than 92% of its total population having completed their vaccination regimen.
COVID-19 vaccination in Iceland is an effort to immunize the adult population of Iceland due to the COVID-19 pandemic. As of July 2021, more than 260,000 individuals had received at least one dose of COVID-19 vaccine, which was over 78% of the country's population. On November 21, 2021, 90% of the target population had been fully vaccinated, while around 1 in 5 people had received a booster on top of that; by December 9, 2021, the share of the population having received a booster shot exceeded 50%. On December 13, 2021, the country began offering Pfizer vaccinations to children aged 5–11.
COVID-19 vaccination in Taiwan is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in response to the ongoing pandemic in the country.
The COVID-19 vaccination in Spain is the national vaccination strategy started on the 27th of December 2020 in order to vaccinate the country's population against COVID-19 within the international effort to fight the COVID-19 pandemic.
The COVID-19 vaccination campaign in Ukraine is an ongoing mass immunization campaign for the COVID-19 pandemic in Ukraine.